Natixis Has $7.80 Million Stock Holdings in CONMED Co. (NYSE:CNMD)

Natixis increased its holdings in shares of CONMED Co. (NYSE:CNMD - Free Report) by 1,069.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,000 shares of the company's stock after purchasing an additional 104,250 shares during the period. Natixis owned approximately 0.37% of CONMED worth $7,802,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of CONMED by 93.6% in the fourth quarter. GAMMA Investing LLC now owns 726 shares of the company's stock worth $50,000 after purchasing an additional 351 shares in the last quarter. Pacer Advisors Inc. lifted its position in CONMED by 41.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,656 shares of the company's stock worth $113,000 after buying an additional 485 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of CONMED by 19.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,962 shares of the company's stock worth $136,000 after buying an additional 322 shares during the last quarter. CIBC Asset Management Inc bought a new position in shares of CONMED in the 4th quarter valued at about $210,000. Finally, Summit Investment Advisors Inc. increased its position in shares of CONMED by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,228 shares of the company's stock valued at $221,000 after acquiring an additional 205 shares during the last quarter.

Analyst Upgrades and Downgrades

CNMD has been the topic of several recent analyst reports. Stifel Nicolaus boosted their price objective on shares of CONMED from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. JPMorgan Chase & Co. lowered CONMED from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $85.00 to $70.00 in a research note on Thursday, February 6th. Wells Fargo & Company reduced their target price on CONMED from $74.00 to $70.00 and set an "equal weight" rating for the company in a research note on Thursday, February 6th. Finally, Needham & Company LLC dropped their price target on CONMED from $97.00 to $91.00 and set a "buy" rating on the stock in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $77.20.

CONMED Price Performance

NYSE CNMD traded down $0.31 during midday trading on Friday, hitting $50.69. The company had a trading volume of 449,367 shares, compared to its average volume of 451,639. The company has a current ratio of 2.30, a quick ratio of 1.06 and a debt-to-equity ratio of 0.94. CONMED Co. has a twelve month low of $46.00 and a twelve month high of $78.58. The company has a market capitalization of $1.57 billion, a PE ratio of 11.96, a P/E/G ratio of 1.83 and a beta of 1.28. The firm has a 50-day moving average price of $56.99 and a 200-day moving average price of $65.14.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. As a group, analysts anticipate that CONMED Co. will post 4.35 earnings per share for the current fiscal year.

CONMED Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.58%. CONMED's payout ratio is currently 18.87%.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.